Post

CiMaas starts 2017 with successful first investment

MAASTRICHT, Mercurius Beleggingsmaatschappij B.V. and Werker Beleggingsmaatschappij B.V.  invest in CiMaas B.V. to realize cancer immunotherapy. CiMaas is now able to start a clinical trial in late 2017 for lung cancer patients with a cellular vaccine that will stimulate the patients’ own immune system to fight the disease.

Post

CiMaas BV and PharmaCell BV enter a collaborative agreement

CiMaas BV, a company developing cellular immunotherapy for cancer, and PharmaCell BV, a leading Contract Manufacturing Organization for Cellular Therapies and Regenerative Medicine in Europe, have agreed to collaborate in the clinical development of CiMaas’ products.

Post

CiMaas appoints Dr. Yvo Graus as Chief Operating Officer

Dr Yvo Graus, PhD, MBA, will join the management team of CiMaas. Yvo Graus is an immunologist and has extensive experience in biotechnology. Through his activities at Genmab, Yvo gained great experience in product development from bench to bedside. He worked on the development of products in the laboratory to making them applicable in patients…. Read more »

Post

CiMaas appoints Drs D.A. van den Noort in Supervisory Board

Drs D.A. van den Noort, MD, and member of the Board of Directors of Bioseutica, has been appointed as first member of the Supervisory Board of CiMaas. Mister van den Noort has tremendous experience in the pharmaceutical industry and is well acquainted with investment instruments in Biotech start-ups. Daan van den Noort: “CiMaas is an… Read more »